These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26929256)

  • 1. Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.
    Opatrná S; Pöpperlová A; Lysák D; Fuchsová R; Trefil L; Racek J; Topolčan O
    Ther Apher Dial; 2016 Apr; 20(2):149-57. PubMed ID: 26929256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
    Opatrna S; Lysak D; Trefil L; Parker C; Topley N
    Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
    Parikova A; Zweers MM; Struijk DG; Krediet RT
    Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
    Fusshoeller A; Plail M; Grabensee B; Plum J
    Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane.
    Moriishi M; Kawanishi H; Watanabe H; Tsuchiya S
    Adv Perit Dial; 2005; 21():21-4. PubMed ID: 16686279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
    Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT
    Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.
    Posthuma N; ter Wee PM; Donker AJ; Oe PL; Peers EM; Verbrugh HA
    Perit Dial Int; 2000; 20 Suppl 2():S106-13. PubMed ID: 10911654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study.
    Pajek J; Kveder R; Bren A; Gucek A; Ihan A; Osredkar J; Lindholm B
    Perit Dial Int; 2008; 28(1):44-52. PubMed ID: 18178947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis.
    Sanusi AA; Zweers MM; Weening JJ; de Waart DR; Struijk DG; Krediet RT
    Perit Dial Int; 2001; 21(5):495-500. PubMed ID: 11757834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.
    Krediet RT
    Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biocompatibility of a bicarbonate/lactate-buffered PD fluid tested with a double-chamber cell culture system.
    Fusshoeller A; Baehr J; Grabensee B; Plum J
    Perit Dial Int; 2005; 25(4):387-93. PubMed ID: 16022097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
    Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
    Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
    Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory factors for hypoalbuminemia in Japanese peritoneal dialysis patients.
    Shioya M; Yoshida T; Kasai K; Furuya R; Kato A; Mori N; Matsumoto Y; Kumagai H
    Nephrology (Carlton); 2013 Aug; 18(8):539-44. PubMed ID: 23718260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients.
    Lopes Barreto D; Coester AM; Noordzij M; Smit W; Struijk DG; Rogers S; de Waart DR; Krediet RT
    Nephrol Dial Transplant; 2011 Nov; 26(11):3739-44. PubMed ID: 21498425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?
    Martikainen TA; Teppo AM; Grönhagen-Riska C; Ekstrand AV
    Perit Dial Int; 2005; 25(5):453-60. PubMed ID: 16178478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis.
    Panorchan K; Davenport A
    BMC Nephrol; 2014 Sep; 15():149. PubMed ID: 25217152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.
    Jones S; Holmes CJ; Krediet RT; Mackenzie R; Faict D; Tranaeus A; Williams JD; Coles GA; Topley N;
    Kidney Int; 2001 Apr; 59(4):1529-38. PubMed ID: 11260417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal follow-up of CA125 in peritoneal effluent.
    Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
    Kidney Int; 1997 Mar; 51(3):888-93. PubMed ID: 9067926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.